key: cord-0796113-1f9lri45
authors: Harari, Rafael; Bangalore, Sripal; Chang, Ernest; Shah, Binita
title: COVID‐19 complicated by acute myocardial infarction with extensive thrombus burden and cardiogenic shock
date: 2020-05-19
journal: Catheter Cardiovasc Interv
DOI: 10.1002/ccd.28992
sha: ec8175888d77de28ebc78a2f776ddce006e17212
doc_id: 796113
cord_uid: 1f9lri45

A patient with coronavirus disease 19 (COVID‐19) developed acute myocardial infarction (AMI) complicated by extensive coronary thrombosis and cardiogenic shock. She underwent percutaneous coronary intervention and placement of a mechanical circulatory support device but subsequently died from shock. This report illustrates the challenges in managing patients with COVID‐19, AMI, and cardiogenic shock.

Coronavirus disease 19 (COVID-19) is associated with serious cardiovascular complications, including acute myocardial infarction (AMI). We present the case of a patient with COVID-19 who developed ST-segment elevation myocardial infarction (STEMI) and cardiogenic shock. Emergent percutaneous coronary intervention (PCI) was complicated by extensive thrombus burden with distal embolization and recurrent stent thrombosis within the newly deployed stent, managed with the administration of intracoronary thrombolytics and eptifibatide. To our knowledge, this is the first report that describes the use of intracoronary thrombolytics in a patient with COVID-19 and recurrent intraprocedural thrombotic complications.

A 40-year-old woman with a history of diabetes mellitus, hypertension, hyperlipidemia, and paranoid schizophrenia presented to the emergency department with retrosternal chest pain for 1 day and cough and shortness of breath for 1 week. She reported exposure to confirmed COVID-19-positive residents in her group home. On admission, she was afebrile (37.5 C), normotensive (124/78 mmHg), but tachycardic (112 beats per minute), and hypoxic (oxygen saturation 84% on room air and 95% on 8 L of oxygen via nasal canula).

Electrocardiogram (ECG) showed sinus tachycardia and left ventricular (LV) hypertrophy ( Figure 1a) . Chest X-ray showed bilateral opacities consistent with pneumonia ( Figure 2 ). Laboratory data are presented in Table 1 . The patient was admitted for treatment of COVID-19 pneumonia and to rule out acute coronary syndrome, treated with an aspirin 325 mg and clopidogrel 600 mg oral load. On the morning of hospital day 2, she reported worsening chest pain. is associated with acute respiratory distress syndrome, acute kidney injury, electrolyte disturbances, and greater risk of inhospital mortality. 10 The management of STEMI in patients with COVID-19 remains controversial, with some regions advocating for initial treatment with thrombolytic therapy in patients without contraindications. 11 However, the United States Society statements advocate against routine IV thrombolytic therapy due to associated bleeding risks, particularly in the potential setting of myocarditis, unless timely PCI is not feasible. 12 Given the very high burden of thrombus in a portion of COVID-19 STEMIs, intracoronary thrombolytic therapy, though, may play a pivotal role. Subsequent to the case illustrated in this report, we successfully treated another patient with COVID-19 and inferior STEMI with high thrombus burden and cardiogenic shock. In this case, unfractionated heparin and IV antiplatelet agents were administered and a 2.0-mm compliant balloon was used to establish flow but extensive thrombus was noted. We subsequently used intracoronary 

Increased thrombotic risk is a well-recognized complication of COVID-19. The management of AMI complicated by extensive thrombus burden in patients with COVID-19 is unclear, and presents a particular challenge with regards to procedural technique and choice of adjunct pharmacotherapy.

Clinical characteristics of coronavirus disease 2019 in China

ST-segment elevation in patients with Covid-19 -a case series

Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19)

Coronavirus disease 2019 (COVID-19) and cardiovascular disease

COVID-19 and the cardiovascular system

The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the experience of clinical immunologists from China

Role of acute infection in triggering acute coronary syndromes

COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Angiogram of the right coronary artery: (a) initial (arrow denotes occlusion), (b) following a 2.0-mm balloon and administration of unfractionated heparin and intravenous antiplatelet agents, (c) following intracoronary tPA and mechanical powered aspiration thrombectomy, and (d) final results. tPA, tissue plasminogen activator

Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol

Recommendations from the Peking Union Medical College Hospital for the management of acute myocardial infarction during the COVID-19 outbreak

Management of acute myocardial infarction during the COVID-19 pandemic. Catheter Cardiovasc Interv. 2020;XXX:XXX. How to cite this article

The authors would like to acknowledge the following physicians for their contributions to our work: Dr Jason Costa, Dr Kinjan Parikh, Dr Norma Keller, and Dr Homam Ibrahim.

https://orcid.org/0000-0002-8528-2267